SEC shines regulatory spotlight on I-Mab, Sinovac and others as more Chinese biotechs scramble to comply with new law
More Chinese biotech companies are being called out as the SEC releases a fresh batch of US-listed companies that may, in a few years, be in breach of a new law and face the threat of delisting.
AbbVie-partnered I-Mab, Covid-19 vaccine maker Sinovac, CAR-T developer Gracell Biotechnologies, Sanofi ally Adagene and little-known Burning Rock Biotech have joined BeiGene, Hutchmed and Zai Lab in a group identified under the Holding Foreign Companies Accountable Act.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.